European Huntington's Disease Network
0 FOLLOWERS
The EHDN believes that facilitating research to advance knowledge is essential as we strive to develop effective therapies for HD. This philosophy is applied in numerous initiatives, including open sharing of data, infrastructure and support, funding opportunities, education and training. One of the EHDN's goals is to improve the care of people affected by HD by developing evidence-based..
European Huntington's Disease Network
5d ago
Episode #1: Introduction: What is Juvenile and Pediatric HD ..read more
European Huntington's Disease Network
1M ago
March 23, 1993 is the date when the mutation that causes Huntington’s disease was first published. We launched Gratitude Day as a way of honoring the families who made this discovery possible ..read more
European Huntington's Disease Network
1M ago
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the bottom of the webpage.
EHDN-NL-Mar2024
..read more
European Huntington's Disease Network
2M ago
We are seeking nominations for the EHDN Executive Committee (EC).
If you are interested in being part of the EC, or would like to nominate somebody ..read more
European Huntington's Disease Network
2M ago
On February 12, 2024, the EHDN has hosted a virtual platform meeting on the Generation-HD1 trial to discuss the previously published data.
The video of this meeting is available ..read more
European Huntington's Disease Network
2M ago
Charles Sabine’s talk represents his personal experience with and understanding of Huntington’s Disease. [available since Feb 8, 2024 ..read more
European Huntington's Disease Network
4M ago
On February 12, 2024, at 16:00 CET (15:00 GMT), EHDN will be hosting a virtual platform meeting to discuss the recently published data on the Generation-HD1 trial (read more). The conference will consist of a presentation by the sponsor, Roche, followed by a Q&A session and a discussion by a panel on open (and answered) questions and the way forward.
The meeting is aimed at professionals, but all are welcome.
– – – Please save the date in your diary – – – More details will follow shortly ..read more
European Huntington's Disease Network
4M ago
Are you a young/recently qualified clinician interested in learning more about HD?
Click here for further details ..read more
European Huntington's Disease Network
4M ago
GENERATION HD1 – This Phase 3 trial was stopped in March 2021 following a benefit–risk assessment by an independent data monitoring committee. A letter published 07/12/2023 in the New England Journal of Medicine (DOI: 10.1056/NEJMc2300400) details ad hoc analyses conducted on the week 69 data. Findings suggest that younger participants with lower disease burden may potentially benefit from tominersen. This is hypothesis is currently being tested in the Phase 2 GENERATION HD2 trial ..read more